Who are the Institutional Holders in G1 Therapeutics Inc (GTHX)?

G1 Therapeutics Inc (NASDAQ: GTHX) is 54.10% higher on its value in year-to-date trading and has touched a low of $1.08 and a high of $7.91 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The GTHX stock was last observed hovering at around $4.83 in the last trading session, with the day’s loss setting it -0.13%.

Currently trading at $4.70, the stock is 21.37% and 47.49% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.4 million and changing -2.69% at the moment leaves the stock 100.49% off its SMA200. GTHX registered -39.59% loss for a year compared to 6-month gain of 133.83%. The firm has a 50-day simple moving average (SMA 50) of $2.64 and a 200-day simple moving average (SMA200) of -$3.63.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

The stock witnessed a 35.45% loss in the last 1 month and extending the period to 3 months gives it a 199.36%, and is 5.38% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.90% over the week and 11.32% over the month.

G1 Therapeutics Inc (GTHX) has around 170 employees, a market worth around $243.65M and $77.89M in sales. Profit margin for the company is -90.82%. Distance from 52-week low is 335.19% and -40.58% from its 52-week high. The company has generated returns on investments over the last 12 months (-71.49%).

G1 Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.27 with sales reaching $13.08M over the same period.The EPS is expected to grow by 71.50% this year, but quarterly earnings will post 57.50% year-over-year. Quarterly sales are estimated to grow 27.60% in year-over-year returns.

96 institutions hold shares in G1 Therapeutics Inc (GTHX), with institutional investors hold 32.40% of the company’s shares. The shares outstanding are 51.50M, and float is at 42.75M with Short Float at 7.61%. Institutions hold 28.89% of the Float.

The top institutional shareholder in the company is Fisher Asset Management, LLC with over 2.54 million shares valued at $6.33 million. The investor’s holdings represent 4.91% of the GTHX Shares outstanding. As of Jun 29, 2023, the second largest holder is JP Morgan Chase & Company with 2.12 million shares valued at $5.27 million to account for 4.09% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 1.95 million shares representing 3.77% and valued at over $4.86 million, while Blackrock Inc. holds 2.29% of the shares totaling 1.19 million with a market value of $2.95 million.

G1 Therapeutics Inc (GTHX) Insider Activity

A total of 0 insider transactions have happened at G1 Therapeutics Inc (GTHX) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by MURDOCK TERRY L, the company’s Chief Operating Officer. SEC filings show that MURDOCK TERRY L sold 721 shares of the company’s common stock on Jan 04 at a price of $2.94 per share for a total of $2121.0. Following the sale, the insider now owns 0.1 million shares.

G1 Therapeutics Inc disclosed in a document filed with the SEC on Jan 04 that Avagliano Mark (Chief Business Officer) sold a total of 721 shares of the company’s common stock. The trade occurred on Jan 04 and was made at $2.94 per share for $2121.0. Following the transaction, the insider now directly holds 0.12 million shares of the GTHX stock.

Still, SEC filings show that on Jan 04, Malik Rajesh (Chief Medical Officer) disposed off 721 shares at an average price of $2.94 for $2121.0. The insider now directly holds 169,938 shares of G1 Therapeutics Inc (GTHX).

G1 Therapeutics Inc (GTHX): Who are the competitors?

One of the company’s main competitors (and peers) include Eli Lilly & Co. (LLY) that is trading 113.17% up over the past 12 months.Roche Holding AG Akt (RO) lies in the list of competitors of the G1 Therapeutics Inc and is -28.04% lower over the same period from GTHXRogers Corp. (ROG) is -22.07% down on the 1-year trading charts.